Form 4: Viracta Therapeutics Director Barry J. Simon Acquires 50,000 Stock Options

Director Barry J. Simon acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024, according to a recent SEC filing.

Summary

• Barry J. Simon, a director of Viracta Therapeutics, Inc., acquired 50,000 stock options on June 20, 2024.
• The exercise price of these options is $0.569 per share.
• The options vest monthly over a 12-month period, or fully upon the next annual stockholder meeting, contingent on continued service.
• The options expire on June 20, 2034.
• A Power of Attorney was executed, authorizing Michael E. Faerm, Mark Rothera, Stewart Brown, Sanja Lazic, Ben Capps, and Brandon Shaw to act on Simon's behalf regarding SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an insider transaction. The acquisition of options could be seen as mildly positive, but it's not a strong indicator of future performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options is contingent on continued service.

Industry Context

This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they have transactions involving the company's securities. It provides transparency to the market about insider activity.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder confidence.

Key Dates

Keywords

stock options, Form 4, Viracta Therapeutics, director, Barry J. Simon, insider trading, SEC filing, VIRX